Vistagen to present at the 2025 american society of clinical psychopharmacology conference

South san francisco, calif.--(business wire)--vistagen (nasdaq: vtgn), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will present at the american society of clinical psychopharmacology (ascp) conference in scottsdale, arizona from may 27-30, 2025. the company's poster presentations will explore the age of onset of social anxiety dis.
VTGN Ratings Summary
VTGN Quant Ranking